Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2941-2948

  Hobisch, A ^a   Ramoner, R ^a   Fuchs, D ^a   Godoy Tundidor, S ^a   Bartsch, G ^a   Klocker, H ^a   Culig, Z ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; REPORTER GENE;

ANDROGENS; BINDING, COMPETITIVE; CELL COUNT; CELL CYCLE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; METRIBOLONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRITIUM; TUMOR CELLS, CULTURED;

EID: 0034817053     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Interleukin-6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression
2. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines
3. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase
4. Interleukin-6: A candidate mediator of human prostate cancer morbidity
5. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer
6. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma
7. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
8. Interleukin-6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia
9. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro
10. Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells
11. Characterization of the role of IL-6 in the progression of prostate cancer
12. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: Implications for the development of metastatic disease
13. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
14. LNCaP model of human prostatic carcinoma
15. Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional regulation of the interleukin 6 gene
16. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway
17. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP
18. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines
19. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding
20. Interleukin-1β mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells
21. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
22. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells
23. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue
24. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6
25. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line
26. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
27. Angiogenesis and hematopoiesis induced by kaposi's sarcoma-associated herpesvirus-encoded interleukin-6
28. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens
29. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow
30. Inhibition of NFκB activity through maintenance of IκBα levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter
31. Repression of the IL-6 gene is associated with hypermethylation
32. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression
33. Down-regulation of interleukin 6 receptor α chain in interleukin 6-transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M
34. Regulation of interleukin-6 receptor expression in human monocytes and hepatocytes
35. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes
36. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest
37. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative
38. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
39. Transforming growth factor-β and prostate cancer
40. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro
41. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer
42. Serum interleukin-6 as a prognostic factor in patients with prostate cancer
43. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity